Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 21, 2012
FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial
S Ladoire, G Mignot, C Dalban, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 24, 2017
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy
K Fizazi, A Ulys, L Sengeløv, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2019
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
A Bamias, K Tzannis, L C Harshman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2017
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
A Bamias, K Tzannis, L C Harshman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 7, 2025
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer
A Mamann, Y Pradat, F C Bidard, et al.
ESMO Open
|
November 26, 2025
PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort
F Cherifi, L Cabel, C Bousrih, et al.
British Journal of Cancer
|
June 25, 2024
Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer
F Poumeaud, M Morisseau, L Cabel, et al.
ESMO Open
|
January 20, 2026
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer
F Lynce, C Valenza, S M Niman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2019
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†
A Horwich, M Babjuk, J Bellmunt, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 21, 2012
FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial
S Ladoire, G Mignot, C Dalban, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 24, 2017
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy
K Fizazi, A Ulys, L Sengeløv, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2019
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
A Bamias, K Tzannis, L C Harshman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2017
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
A Bamias, K Tzannis, L C Harshman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 7, 2025
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer
A Mamann, Y Pradat, F C Bidard, et al.
ESMO Open
|
November 26, 2025
PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort
F Cherifi, L Cabel, C Bousrih, et al.
British Journal of Cancer
|
June 25, 2024
Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer
F Poumeaud, M Morisseau, L Cabel, et al.
ESMO Open
|
January 20, 2026
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer
F Lynce, C Valenza, S M Niman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2019
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†
A Horwich, M Babjuk, J Bellmunt, et al.
Page
of 2